26.38
-0.11 (-0.42%)
| Previous Close | 26.49 |
| Open | 26.32 |
| Volume | 661,310 |
| Avg. Volume (3M) | 1,900,722 |
| Market Cap | 2,479,859,712 |
| Price / Sales | 13.14 |
| Price / Book | 31.31 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 |
| Diluted EPS (TTM) | -2.36 |
| Total Debt/Equity (MRQ) | 84.10% |
| Current Ratio (MRQ) | 3.88 |
| Operating Cash Flow (TTM) | -188.78 M |
| Levered Free Cash Flow (TTM) | -102.02 M |
| Return on Assets (TTM) | -67.10% |
| Return on Equity (TTM) | -183.07% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | 0.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.10 |
|
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (“TGFβ1”), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.07% |
| % Held by Institutions | 98.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Polar Capital Holdings Plc | 30 Sep 2024 | 2,940,672 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 42.00 (Piper Sandler, 59.21%) | Buy |
| Median | 38.00 (44.05%) | |
| Low | 31.00 (JP Morgan, 17.51%) | Buy |
| Average | 37.60 (42.53%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 28.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Nov 2024 | 40.00 (51.63%) | Buy | 26.66 |
| 08 Oct 2024 | 35.00 (32.68%) | Buy | 29.49 | |
| Piper Sandler | 15 Oct 2024 | 42.00 (59.21%) | Buy | 28.54 |
| JP Morgan | 14 Oct 2024 | 31.00 (17.51%) | Buy | 28.52 |
| 03 Oct 2024 | 18.00 (-31.77%) | Buy | 7.07 | |
| BMO Capital | 11 Oct 2024 | 38.00 (44.05%) | Buy | 26.51 |
| Wedbush | 07 Oct 2024 | 37.00 (40.26%) | Buy | 34.28 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GILMAN MICHAEL | 26.66 | 26.66 | 0 | 0 |
| MARANTZ JING L. | - | 28.15 | -2,105 | -59,256 |
| Aggregate Net Quantity | -2,105 | |||
| Aggregate Net Value ($) | -59,256 | |||
| Aggregate Avg. Buy ($) | 26.66 | |||
| Aggregate Avg. Sell ($) | 27.41 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GILMAN MICHAEL | Director | 12 Nov 2024 | Disposed (-) | 37,459 | 26.66 | 998,657 |
| GILMAN MICHAEL | Director | 12 Nov 2024 | Acquired (+) | 37,459 | 26.66 | 998,657 |
| MARANTZ JING L. | Officer | 11 Nov 2024 | Automatic sell (-) | 2,105 | 28.15 | 59,256 |
| MARANTZ JING L. | Officer | 11 Nov 2024 | Option execute | 2,105 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |